Price-sensitive press releases
2025-06-30
STOCKHOLM, June 30[th], 2025, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 48,712,067. The 832,213 newly issued shares are held by the company to secure its commitments under the incentive program.
2025-06-25
Following the announcement in Moberg Pharma’s interim report for the period January–March 2025, the company has conducted a review of its resource allocation. The need for resources in clinical development in particular has decreased, while the needs within commercialization is increasing as a result of ongoing and planned launches in Europe. As part of this transition, the company’s management team is being streamlined.
2025-06-16
Moberg Pharma AB (OMX: MOB) announces that Terclara[®], the company's innovative drug for treatment of nail fungus, is now the market leader also in Norway. This means that Terclara[®] is now the leading product in both Sweden and Norway, a testament to the product's strong impact among both pharmacies and consumers.
2025-06-03
Moberg Pharma AB (publ) today announces that the board of directors exercises authorizations to issue and repurchase class C shares, and converts class C shares to common shares, to secure the company’s commitments under incentive programmes and for the purpose of covering certain costs that may arise as a result of incentive programs.
2025-05-22
STOCKHOLM, May 22[th], 2025. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2025-05-13
TERCLARA NOW ALSO AVAILABLE IN NORWAY
2025-04-22
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 22 May 2025 at 16:30 at Advokatfirman Schjødt, Hamngatan 27 in Stockholm.
2025-04-11
Moberg Pharma´s Annual report for 2024 has been published and is available on www.mobergpharma.com (https://www.mobergpharma.com/investors/annual-reports)
2025-02-11
TERCLARA CONTINUES TO LEAD THE MARKET AND EXPANDS TO NORWAY